Last reviewed · How we verify
propofol, remifentanil, sevoflurane
At a glance
| Generic name | propofol, remifentanil, sevoflurane |
|---|---|
| Also known as | diprivan, ultiva |
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Equivalent MAC in General Anesthesia
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- qCON/qNOX-Guided Anesthesia in Patients Undergoing Thyroidectomy Surgery (NA)
- The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery (PHASE4)
- Continuous Versus 1-min Oscillometric Arterial BP Monitoring (NA)
- The Effects of Three Different Anesthetic Methods on Postoperative Agitation (NA)
- Comparison of the Effects of Total Intravenous Anaesthesia With Target-Controlled Infusion (TCI) and Inhalation Anaesthesia on Airway Complications During Extubation and in the Early Postoperative Period in Thyroidectomy Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- propofol, remifentanil, sevoflurane CI brief — competitive landscape report
- propofol, remifentanil, sevoflurane updates RSS · CI watch RSS
- Asan Medical Center portfolio CI